Express Scripts Sees Rx Drug Cost Increases Under 10% As Manageable
Executive Summary
Active management of pharmacy benefits that results in prescription cost increases of less than 10% would be acceptable to Express Scripts.
You may also be interested in...
Express Scripts Expects To Secure Leading Role In MD Prescribing Devices
Express Scripts expects the complexity of its formulary services will help the PBM to secure a leading role in the use of hand-held physician prescribing devices.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials